OSUR
HealthcareOraSure Technologies, Inc.
$2.47
+$0.09 (+3.78%)
Jan 5, 2026
Price History (1Y)
Analysis
OraSure Technologies, Inc. is a healthcare company that operates in the Medical Instruments & Supplies industry within the Healthcare sector. The company has a market capitalization of $180.65 million, annual revenue of $125.70 million, and approximately 501 employees. The company's financial health appears to be challenging, with negative profitability metrics. OraSure Technologies reported an operating margin of -58.0%, a profit margin of -47.9%, and net income of -$60.23 million (TTM). The company also has significant cash reserves, totaling $216.48 million, but carries relatively low debt of $13.46 million. The valuation context for OraSure Technologies is characterized by negative profitability metrics and growth rates. The forward P/E ratio stands at -4.53, indicating a potential loss in the next fiscal year. Revenue growth has declined by 32.1% on a year-over-year basis, while earnings growth rate is not available (N/A). The company's dividend yield is also N/A, and it does not pay dividends as indicated by the payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About OraSure Technologies, Inc.
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $180.65M
- P/E Ratio
- N/A
- 52-Week High
- $4.22
- 52-Week Low
- $2.08
- Avg Volume
- 664.33K
- Beta
- 0.77
Company Info
- Industry
- Medical Instruments & Supplies
- Exchange
- NMS
- Country
- United States
- Employees
- 501